Evidence map›Paper›PMID 34948122›Full record

ArticleInternational journal of molecular sciences2021

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors.

Watson P Folk, Alpana Kumari, Tetsushi Iwasaki, Erica K Cassimere, Slovénie Pyndiah, Elizabeth Martin, Kelly Homlar, Daitoku Sakamuro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. BIN1 in cancer: biomarker and therapeutic target.Journal of cancer research and clinical oncology · 2023
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Watson P FolkDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Alpana KumariDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Tetsushi IwasakiDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Erica K CassimereDepartment of Biology, College of Science, Engineering and Technology, Texas Southern University, Houston, TX 77004, USA.
Slovénie PyndiahLes Francs Bourgeois-La Salle, 75004 Paris, France.
Elizabeth MartinGeorgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
Kelly HomlarGeorgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
Daitoku SakamuroDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.ORCID 0000-0002-5831-7022
Augusta University · USTexas Southern University · US

Funding

Foundation for the National Institutes of Health R01CA140379
6 · The paper itself

Abstract

The pro-apoptotic tumor suppressor BIN1 inhibits the activities of the neoplastic transcription factor MYC, poly (ADP-ribose) polymerase-1 (PARP1), and ATM Ser/Thr kinase (ATM) by separate mechanisms. Although BIN1 deficits increase cancer-cell resistance to DNA-damaging chemotherapeutics, such as cisplatin, it is not fully understood when BIN1 deficiency occurs and how it provokes cisplatin resistance. Here, we report that the coordinated actions of MYC, PARP1, and ATM assist cancer cells in acquiring cisplatin resistance by

Indexed as

Ataxia Telangiectasia Mutated ProteinsCell Line, TumorCisplatinDrug Resistance, NeoplasmHumansNeoplasm ProteinsNeoplasmsPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProtein Kinase InhibitorsAtaxia Telangiectasia Mutated ProteinsATM protein, humanCisplatinNeoplasm ProteinsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProtein Kinase InhibitorsapoptosisATMBIN1cisplatin resistanceMDC1-RNF8 complexMYCPARP1

Identifiers

PMID34948122
PMCPMC8704450
OpenAlexW4200302963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.